Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma: A Randomized Pilot Trial. (AvastinvsMMC)

NCT02901236 Phase 2/Phase 3 COMPLETED

Refractory glaucoma often requires vision-sparing trabeculectomy. To increase surgical success, adjunctive pharmacotherapy is utilized albeit the risk of adverse events. This prospective trial randomizes adults with uncontrolled glaucoma to assess an emerging healing modulatory strategy. Over a 1-year follow-up, trabeculectomy complemented with intracameral delivery of anti-angiogenic bevacizumab (1.25 mg) is compared to standard trabeculectomy with anti-fibrotic mitomycin-C (0.02%; applied for 2 minutes).

Details

Lead sponsor	Athens Vision Eye Institute
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	40
Start date	2014-01
Completion	2016-01

Conditions

• Glaucoma

Interventions

• Standard Guarded Trabeculectomy
• Mitomycin C
• Bevacizumab

Primary outcomes

• Intraocular Pressure — 1 year after the intervention
  Intraocular pressure measured by Goldmann applanation tonometry was declared the primary outcome measure